美国ChemoCentryx
ChemoCentryx公司正在开发用于治疗自身免疫性疾病、炎性疾病和肿瘤的口服药物，这些药物主要针对趋化因子和化学诱导系统。
ChemoCentryx公司最领先的药物是Traficet-EN，目前处于治疗克罗恩病的Ⅲ期临床试验阶段和乳糜泻的Ⅱ期临床阶段以及溃疡性结肠炎的I期临床研究阶段。另外，该公司还有一些药物处于I期临床阶段，分别是治疗胃肠道疾病的CCX025、治疗脉管狭窄和多发性硬化症的CCX140以及治疗类风湿性关节炎的CCX354。



ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.